Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 6/20 | 0.72 |
| ▸ | PSEN2 | P49810 | 6/20 | 0.72 |
| ▸ | APH1B | Q8WW43 | 6/20 | 0.72 |
| ▸ | NCSTN | Q92542 | 6/20 | 0.72 |
| ▸ | APH1A | Q96BI3 | 6/20 | 0.72 |
| ▸ | PSENEN | Q9NZ42 | 6/20 | 0.72 |
| ▸ | ACHE | P22303 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | CTSG | P08311 | 1/20 | 0.54 |
| ▸ | CMA1 | P23946 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 2/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2220964 | 0.98 | PSEN1 (0.70) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9144277 | 0.89 | PSEN1 (0.72) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2219908 | 0.88 | PSEN1 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2222394 | 0.88 | PSEN1 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL916558 | 0.88 | PSEN1 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2217801 | 0.88 | PSEN1 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8251036 | 0.88 | PSEN1 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2220391 | 0.87 | PSEN1 (0.60) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2221045 | 0.87 | PSEN1 (0.60) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8273877 | 0.86 | PSEN1 (0.56) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178119-A1 | Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | US | claimed |
| EP-1915371-A2 | BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals Inc. (US) | 2008-04-30 | — | — | EP | claimed |
| WO-2007024651-A2 | BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | claimed |
| US-20110178119-A1 | Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase | ELAN PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| EP-1915371-A2 | BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | Elan Pharmaceuticals Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007024651-A2 | BRIDGED N-BICYCLIC SULFONAMIDO INHIBITORS OF GAMMA SECRETASE | ELAN PHARMACEUTICALS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178119-A1 | Bridged N-Bicyclic Sulfonamido Inhibitors of Gamma Secretase | BACE1, BACE2, PSEN1 | PSEN1 3/4885PSEN2 4/4885APH1B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.